A world leader in the development and integration of innovative materials and components, Saint-Gobain creates customized single-use solutions for the biopharmaceutical market. Through our unparalleled technological expertise and worldwide resources, we develop integrated solutions for critical fluid management that meet your evolving needs.
April 9, 2019 - Hitachi Chemical Advanced Therapeutics Solutions, LLC (HCATS), a US subsidiary of Hitachi Chemical Co. Ltd. that engages in contract manufacturing and development of cell therapy products, and Saint-Gobain, a global leader in single-use solutions for the Biopharmaceutical industry, today announced a joint development agreement to co-develop and commercialize novel technology solutions, specifically for the cell therapy industry. This collaboration will allow both parties to leverage their decades of experience and unique capabilities to address manufacturing needs of cell therapy product developers and challenges such as CAR-T genetic modification and culture and closed in-process product sampling.
April 08th, 2019
December 20th, 2018